Path Fertility, the commercial brand of Salt Lake City-based molecular diagnostics company Inherent Biosciences, has received a $2 million research grant from the National Institutes of Health to develop an epigenetic diagnostic test for severe male infertility and associated health risks.
The two-year Direct to Phase II Small Business Innovation Research award was provided by the Eunice Kennedy Shriver National Institute of Child Health and Human Development.
The grant will fund development and clinical validation of a diagnostic for non-obstructive azoospermia, a severe form of male infertility characterized by absent sperm in semen due to impaired sperm production.
The condition affects approximately 1% of men worldwide and has been associated with elevated risks of certain cancers and cardiovascular diseases.
Path Fertility is developing a test to identify epigenetic changes involving MSH5, a gene associated with DNA repair.
Previous research supported by Inherent Biosciences identified epigenetic modifications, or epimutations, involving MSH5 in up to 19% of men with non-obstructive azoospermia.
The company believes these findings could help explain some cases that remain unresolved after conventional genetic testing.
Under the grant, Path Fertility will conduct a multicenter clinical study to determine how frequently these changes occur in a broader population of affected men.
The company also plans to develop a semen-based test that could avoid requiring a separate blood sample.
Additional research will examine MSH5 epimutations in 500 patients with colorectal cancer to investigate potential connections with DNA repair abnormalities.
The diagnostic will undergo validation in a CLIA-certified laboratory as Path Fertility prepares for potential commercial introduction as a laboratory-developed test.
The technology is intended to complement NOA Guide, the company’s diagnostic platform designed to help predict the likelihood of successful surgical sperm retrieval.
Alongside the funding announcement, Path Fertility presented research at the American Society for Reproductive Medicine’s 2026 Scientific Congress in Baltimore.
One study evaluated sperm-derived cell-free DNA in 67 men undergoing surgical sperm retrieval.
The researchers reported that cell-free DNA measurements, interpreted alongside follicle-stimulating hormone levels, showed potential for predicting retrieval outcomes.
Another study analyzed real-world data from 537 men tested with Path Fertility’s SpermQT diagnostic across 10 U.S. fertility clinics.
Among 202 couples undergoing intrauterine insemination, the company reported a cumulative pregnancy rate of 22% for men with normal SpermQT results, compared with 0% for those with abnormal results.
The findings were presented as research results and will require appropriate clinical interpretation and further validation.
Path Fertility intends to use the NIH grant to expand its diagnostic capabilities and help clinicians better understand male infertility and associated health considerations.
KEY QUOTES:
“Men with non-obstructive azoospermia are often told there is no explanation for their infertility, and rarely told it may signal risks to their overall health. Our earlier work found MSH5 epimutations in nearly one in five of these men. This award lets us confirm that finding across multiple clinical sites and turn it into a simple semen-based test that gives men a real answer and flags health risks that deserve follow-up.”
Kristin Brogaard, Ph.D., Co-Founder And Chief Scientific Officer Of Path Fertility
“This award is a strong vote of confidence in epigenetics as the foundation for better male fertility diagnostics. With SpermQT, we showed that a ‘normal’ semen analysis can miss subfertile men. With NIH support, we’re extending that platform to men facing the most severe infertility, and the data we’re presenting at ASRM show the same approach producing actionable answers across male fertility care.”
Andy Olson, Co-Founder And CEO Of Path Fertility

